Yüksel Ürün: U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy

Yüksel Ürün shared on X:

“U.S. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy.

• Approved with carboplatin/paclitaxel, then single-agent dostarlimab-gxly, for primary advanced/recurrent endometrial cancer.
• Median OS 44.6 months vs. 28.2 months.
• Common adverse reactions: anemia, fatigue, neuropathy.”

Source: Yüksel Ürün/X

Other posts featuring Yüksel Ürün on OncoDaily.

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.